Seven new biologic agents approved in 2001.
Piascik
Peggy
P
College of Pharmacy, University of Kentucky, Lexington, USA.
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000998:Antiviral Agents / Q000737:chemistry; D000068256:Darbepoetin alfa; D017277:Drug Approval; D004921:Erythropoietin / Q000031:analogs & derivatives; D022362:Hepatitis A Vaccines; D017325:Hepatitis B Vaccines; D006801:Humans; D007140:Immunoglobulin Fab Fragments; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000737:chemistry; D053590:Interleukin 1 Receptor Antagonist Protein; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012795:Sialoglycoproteins; D014481:United States; D014486:United States Food and Drug Administration; D017778:Vaccines, Combined
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000998:Antiviral Agents; D022362:Hepatitis A Vaccines; D017325:Hepatitis B Vaccines; C507763:IL1RN protein, human; D007140:Immunoglobulin Fab Fragments; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D053590:Interleukin 1 Receptor Antagonist Protein; D011994:Recombinant Proteins; D012795:Sialoglycoproteins; D017778:Vaccines, Combined; C050199:digoxin antibodies Fab fragments; C433226:twinrix; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D011092:Polyethylene Glycols